The question of targeting process or disease pattern instead of specific disease entities is already being challenged52 and being explored in the progressive disease phenotype studies.53 With the additional prospect of new drug compounds such as calpain inhibitors or autotaxin inhibitors, an exciting paradigm shift in ILD management is awaited. The gene discussed is ENPP2; the disease is interstitial lung disease.